The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Find insight on Novarti, Sanofi and more in the latest Market Talks covering Health Care.

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

A prostate cancer diagnosis can feel overwhelming, but the growing number of targeted treatments means patients (and their ...

Pluvicto is currently approved for metastatic castration-resistant prostate cancer (mCRPC). Given that nearly all mHSPC patients eventually progress to mCRPC, these new data suggest its potential ...

The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...